Search PubMed⌕ Search

Biomedical subjects

P Baruch

Publications and source records attributed to P Baruch.

25 records · Page 2Linked to original sources
PubMedDate not supplied

Clinical psychomotor retardation and attention in depression.

The importance of the cognitive component in depressive clinical psychomotor retardation is well-recognized, but the underlying information-processing dysfunction has not been precisely investigated. Thirty unmedicated major depressives were concurrently assessed using the Depressive Retardation Rating Scale (DRRS) and an attentional battery in order to evaluate selective and divided attention. Results were analysed following dimensional and categorical approaches. The depressive episode intensity and the associated anxiety did not correlate with any of the attentional variables. However, significant correlations were observed between the DRRS score and every attentional task. Results of the categorical analysis contrasting attentional performances of depressives with and without clinical psychomotor retardation argued for the existence of a link between psychomotor retardation and a global attentional deficit. This study attests to the value of clinical psychomotor retardation as a predictor of cognitive deficits in depressed patients.

Adult↗
PubMedDate not supplied

[Blood pressure control and quality of life: a comparative multicenter double-blind and cross-over trial of labetalol and captopril].

The purpose of this multicenter randomised, double-blind and cross-over study was to compare the antihypertensive effects of labetalol (L) and captopril (C) in 42 moderate hypertensive patients (mean age: 52 years). The drugs were given during two 4-weeks periods at the end of which the systolic (SBP) and diastolic blood pressures (DBP) were measured at rest in supine and standing positions. The assessment of the quality of life was realized with 4 scales completed by the practitioner [anxiety, depression, well-being, visual analog scale (VAS)] and 4 scales of auto-assessment completed by the patient [2 VAS, well-being, sub-scale of pleasure]. At the end of the first treatment's period (D28), both drugs had decreased significantly supine SBP and DBP (p less than 0.001), standing DBP (L = p less than 0.01; C = p less than 0.05), while only L lowered supine SBP (p less than 0.01). The cross-over analysis was unable to conclude, due to the number of patients and a significant interaction which reduced its power. Thus the effect of the first treatment's period seemed to influence the efficacy of the second one. The percentages of patients with a controlled BP were respectively: after 4 weeks of treatment, L = 61 p. 100 vs C = 42 p. 100 and at the end of study (D56), L = 67 p. 100 vs C = 64 p. 100. The cross-over analysis didn't show any difference between the effects of L and C on the quality of life.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMedDate not supplied

[Carpipramine].

Explore the source record for details and available documents.

Adult↗
PubMedDate not supplied

[Perphenazine enanthate. Results of a 1-year open multicenter study].

The results of a one-year, open multicenter trial of perphenazine enanthate, a sustained-release neuroleptic drug, are reported. 240 patients (62% suffering from schizophrenia) were included in the study and 144 were followed during the 12-month period. The usual adverse reactions associated with sustained-release neuroleptic drugs were observed. Total and partial BPRS ratings showed that improvement (expressed as a percentage) after 12 months' treatment was similar for systematized chronic delusions, paranoid schizophrenia and hebephrenia. However, the onset of therapeutic activity was different in these three groups of patients. Maximum therapeutic activity, as defined by the BPRS rating, was obtained within 4 months in chronic delusions whereas schizophrenia improved more progressively. Such patients therefore require prolonged treatment before the therapeutic activity of a sustained-release neuroleptic drug can be assessed.

Adult↗